Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 99.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,196 shares of the biopharmaceutical company’s stock after purchasing an additional 4,583 shares during the period. TD Waterhouse Canada Inc.’s holdings in Regeneron Pharmaceuticals were worth $5,513,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. State Street Corp grew its position in Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock worth $2,536,801,000 after buying an additional 42,343 shares during the last quarter. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock worth $1,214,585,000 after acquiring an additional 36,821 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after acquiring an additional 305,089 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $628,151,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on REGN. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. HSBC assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target on the stock. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $784.77.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
• Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
• Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
• Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
• Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
• Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
• Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $741.45 on Friday. The company has a market capitalization of $77.93 billion, a PE ratio of 17.76, a PEG ratio of 1.95 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The company’s 50 day moving average price is $758.39 and its 200 day moving average price is $649.85. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.